title: Serial Patterns of Ovarian Cancer Biomarkers in a Prediagnosis Longitudinal Dataset.
abstract: Early detection of ovarian cancer through screening may have impact on mortality from the disease. Approaches based on CA125 cut-off have not been effective. Longitudinal algorithms such as the Risk of Ovarian Cancer Algorithm (ROCA) to interpret CA125 have been shown to have higher sensitivity and specificity than a single cut-off. The aim of this study was to investigate whether other ovarian cancer-related biomarkers, Human Epididymis 4 (HE4), glycodelin, mesothelin, matrix metalloproteinase 7 (MMP7), and cytokeratin 19 fragment (CYFRA 21-1), could improve the performance of CA125 in detecting ovarian cancer earlier. Serum samples (single and serial) predating diagnosis from 47 women taking part in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) who went on to develop primary invasive ovarian, fallopian tube, or peritoneal cancer (index cancer) (170 samples) and 179 matched controls (893 samples) were included in the study. A multiplex immunobased assay platform (Becton Dickinson) allowing simultaneous measurement of the six serum markers was used. The area under the ROC curve for the panel of three biomarkers (CA125, HE4, and glycodelin) was higher than for CA125 alone for all analysed time groups, indicating that these markers can improve on sensitivity of CA125 alone for ovarian cancer detection.
authors.affiliation: Women's Cancer, Institute for Women's Health, University College London, Gower Street, London WC1E 6BT, UK.
authors.forename: Oleg
authors.initials: O
authors.lastname: Blyuss
authors.affiliation: Women's Cancer, Institute for Women's Health, University College London, Gower Street, London WC1E 6BT, UK.
authors.forename: Alex
authors.initials: A
authors.lastname: Gentry-Maharaj
authors.affiliation: Women's Cancer, Institute for Women's Health, University College London, Gower Street, London WC1E 6BT, UK.
authors.forename: Evangelia-Orania
authors.initials: EO
authors.lastname: Fourkala
authors.affiliation: Women's Cancer, Institute for Women's Health, University College London, Gower Street, London WC1E 6BT, UK.
authors.forename: Andy
authors.initials: A
authors.lastname: Ryan
authors.affiliation: Women's Cancer, Institute for Women's Health, University College London, Gower Street, London WC1E 6BT, UK.
authors.forename: Alexey
authors.initials: A
authors.lastname: Zaikin
authors.affiliation: Women's Cancer, Institute for Women's Health, University College London, Gower Street, London WC1E 6BT, UK.
authors.forename: Usha
authors.initials: U
authors.lastname: Menon
authors.affiliation: Women's Cancer, Institute for Women's Health, University College London, Gower Street, London WC1E 6BT, UK; University of New South Wales, Sydney, NSW 2052, Australia.
authors.forename: Ian
authors.initials: I
authors.lastname: Jacobs
authors.affiliation: Women's Cancer, Institute for Women's Health, University College London, Gower Street, London WC1E 6BT, UK.
authors.forename: John F
authors.initials: JF
authors.lastname: Timms
mesh_terms: D000328:Adult; D000465:Algorithms; D014408:Biomarkers, Tumor / Q000378:metabolism*; D066264:Datasets as Topic; D005260:Female; D006801:Humans; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000378:metabolism*; D010051:Ovarian Neoplasms / Q000000981:diagnostic imaging* / Q000378:metabolism*; D011859:Radiography
chemical_list: D014408:Biomarkers, Tumor; D009363:Neoplasm Proteins
references.citation: Gynecol Oncol. 2015 Sep;138(3):640-6
references.pmid: 26086566
references.citation: Cancer Res. 2003 Jul 1;63(13):3695-700
references.pmid: 12839961
references.citation: Gynecol Oncol. 2004 Oct;95(1):9-15
references.pmid: 15385104
references.citation: Anticancer Res. 1994 Nov-Dec;14(6B):2743-6
references.pmid: 7532929
references.citation: Anticancer Res. 2005 May-Jun;25(3A):1639-44
references.pmid: 16033074
references.citation: Gynecol Oncol. 2008 Sep;110(3):374-82
references.pmid: 18584856
references.citation: J Natl Cancer Inst. 2008 Oct 15;100(20):1432-8
references.pmid: 18840817
references.citation: Med Oncol. 2014 Jan;31(1):808
references.pmid: 24323399
references.citation: Gynecol Oncol. 2012 Nov;127(2):379-83
references.pmid: 22835718
references.citation: J Natl Cancer Inst. 2011 Nov 2;103(21):1630-4
references.pmid: 21917606
references.citation: JAMA. 2011 Jun 8;305(22):2295-303
references.pmid: 21642681
references.citation: Gynecol Oncol. 2011 Jun 1;121(3):487-91
references.pmid: 21420727
references.citation: Clin Chem Lab Med. 2011 Mar;49(3):521-5
references.pmid: 21288178
references.citation: Cancer Prev Res (Phila). 2011 Mar;4(3):365-74
references.pmid: 21372036
references.citation: Br J Cancer. 2011 Mar 1;104(5):863-70
references.pmid: 21304524
references.citation: Gynecol Oncol. 2010 Mar;116(3):378-83
references.pmid: 19945742
references.citation: J Natl Cancer Inst. 2010 Jan 6;102(1):26-38
references.pmid: 20042715
references.citation: Gynecol Oncol. 2009 Jan;112(1):40-6
references.pmid: 18851871
references.citation: Obstet Gynecol. 2009 Apr;113(4):775-82
references.pmid: 19305319
references.citation: Biometrics. 1988 Sep;44(3):837-45
references.pmid: 3203132
references.citation: Lancet Oncol. 2009 Apr;10(4):327-40
references.pmid: 19282241